NDASUBCUTANEOUSSOLUTION
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
5/8 — Partial
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYMLOS (abaloparatide) is a parathyroid hormone-related peptide (PTHrP) analog administered via subcutaneous injection for the treatment of postmenopausal women with osteoporosis at high risk of fracture. It works by mimicking PTHrP signaling to stimulate bone formation and increase bone mineral density. The drug represents an alternative mechanism to traditional bisphosphonates in the osteoporosis treatment armamentarium.
$0.198BPart D
Peak13.4 years to LOETYMLOS remains in peak commercial phase with $198M in annual Part D spending, suggesting a stable mid-sized brand team focused on market penetration and patient retention strategies.
Mechanism of Action
Pharmacologic Class:
Parathyroid Hormone-Related Peptide Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Started Jun 2025
282 enrolled
Postmenopausal Women With Osteoporosis
Supracondylar Distal Femur Fractures and Abaloparatide
Started Jun 2024
0Femoral Fractures
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
Started Jul 2021
22,054 enrolled
Osteoporosis, Postmenopausal
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Started Feb 2021
70 enrolled
Osteoporosis, Postmenopausal
Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.
Started Nov 2020
52 enrolled
Healthy Volunteers
Worked on TYMLOS at Radius Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.